GSK evaluates PTH analogue option on positive Phase II from Unigene
This article was originally published in Scrip
Executive Summary
Peptide-based therapeutics company, Unigene Laboratories, has reported positive top-line results for its investigational oral parathyroid hormone (PTH) analogue for the treatment of osteoporosis in postmenopausal women.